Kymera Therapeutics (KYMR) total liabilities
Kymera Therapeutics (KYMR) had total liabilities of $163.15M at the end of fiscal 2025 (December 31, 2025). That is 14.6% higher than the $142.42M of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $163.15M
- Change on fiscal 2024
- +14.6%
- Growth, 5 years
- −4.3% a year
- Highest on record
- $203.29Mfiscal 2020
- Lowest on record
- $82.03Mfiscal 2019
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Kymera Therapeutics total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities shrank at a compound 4.3% a year. Across the 7 fiscal years on record (2019–2025), the highest was $203.29M in fiscal 2020 and the lowest $82.03M in fiscal 2019.
Total liabilities by fiscal year
Kymera Therapeutics total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $163.15M | 14.6% up | |
| 2024 | $142.42M | 21.2% down | |
| 2023 | $180.79M | 60.0% up | |
| 2022 | $112.98M | 22.8% down | |
| 2021 | $146.27M | 28.0% down | |
| 2020 | $203.29M | 147.8% up | |
| 2019 | $82.03M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Fresenius Medical Care FMS | €16.72B | 2025 |
| Kymera Therapeutics KYMR | $163.15M | 2025 |
| DaVita DVA | $16.32B | 2025 |
| Halozyme Therapeutics HALO | $2.48B | 2025 |
| Universal Health Services UHS | $8.12B | 2025 |
| Repligen RGEN | $843.57M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Kymera Therapeutics, figure by figure
- Kymera Therapeutics market cap
- Kymera Therapeutics revenue
- Kymera Therapeutics earnings
- Kymera Therapeutics earnings per share (EPS)
- Kymera Therapeutics P/E ratio
- Kymera Therapeutics P/S ratio
- Kymera Therapeutics P/B ratio
- Kymera Therapeutics free cash flow
- Kymera Therapeutics operating margin
- Kymera Therapeutics dividend
- Kymera Therapeutics shares outstanding
- Kymera Therapeutics total debt
- Kymera Therapeutics cash on hand
- Kymera Therapeutics total assets
- Kymera Therapeutics net assets (shareholders' equity)
- Kymera Therapeutics return on equity (ROE)
- Kymera Therapeutics return on invested capital (ROIC)
Kymera Therapeutics (KYMR) overview: price, valuation and scorecardAll health care companies by market value
Kymera Therapeutics total liabilities: questions and answers
How large are Kymera Therapeutics's total liabilities?
Kymera Therapeutics (KYMR) had total liabilities of $163.15M at the end of fiscal 2025 (December 31, 2025). That is 14.6% higher than the $142.42M of fiscal 2024.
What is the growth rate of Kymera Therapeutics's total liabilities?
Over the five fiscal years to 2025 total liabilities shrank at a compound 4.3% a year.
What are the highest and lowest total liabilities figures on record for Kymera Therapeutics?
Across the 7 fiscal years on record (2019–2025), the highest was $203.29M in fiscal 2020 and the lowest $82.03M in fiscal 2019.
How is Kymera Therapeutics's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Kymera Therapeutics it is on record here for 7 fiscal years, 2019 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Kymera Therapeutics (KYMR) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/KYMR/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.